Overview

Background

Robert Francis Kennedy Jr., born January 17, 1954, is an American politician, environmental lawyer, author, and anti-vaccine activist. A member of the prominent Kennedy family, he is a son of Senator and U.S. Attorney General Robert F. Kennedy and a nephew of President John F. Kennedy and Senator Ted Kennedy. He was educated at Harvard University, briefly attended the London School of Economics, and received his law degree from the University of Virginia, as well as an LLM from Pace University.

Kennedy previously sought the Democratic presidential nomination before running as an independent and eventually abandoning his campaign to endorse Trump. His decades-long career as an environmental litigator gave him credibility on ecological issues, but it was his long-standing skepticism of vaccines and pharmaceutical regulation that defined his public profile and animated his MAHA movement. Kennedy was grilled by the Senate Finance Committee at two confirmation hearings, including over his anti-vaccine stance. At the hearings, he stated he was not anti-vaccine but "pro safety," and that he believed vaccines played a critical role in healthcare, although he refused to say he agreed with scientific studies that find vaccines do not cause autism.

The Senate on February 13, 2025, voted 52 to 48 to confirm Kennedy as the 26th Secretary of HHS. Senator Mitch McConnell of Kentucky was the only Republican to join all Democratic senators in voting against his confirmation.

Public Role in the Second Trump Administration

The Make America Healthy Again Agenda

Immediately following Kennedy's swearing-in ceremony, President Trump signed the executive order "Establishing the President's Make America Healthy Again Commission" to investigate and address the root causes of America's escalating health crisis, with a focus on childhood chronic disease. The initiative outlines a broad strategy to address rising health care costs, chronic disease, and preventive care. Kennedy has stated that one of his main missions as HHS Secretary is to make America healthy again by tackling chronic childhood diseases and addressing over-processed foods that are fueling obesity, a major risk factor contributing to chronic diseases such as cardiovascular disease, heart disease, and stroke.

The MAHA agenda has produced a range of specific policy efforts. A directive to close the GRAS ("Generally Recognized as Safe") loophole, issued by Kennedy in March 2025, remains a proposed rule pending White House review, and an official definition of ultra-processed food, announced in June 2025, remains unfinalized. The USDA has approved waivers in 23 states allowing restrictions on SNAP purchases of items such as soda and candy, with implementation beginning in January 2026 in five states. The USDA and HHS have also conducted a "line-by-line" review of the 2025 Dietary Guidelines for Americans released by the Biden administration.

The Make America Healthy Again Commission proposed more than 100 moves to address the root causes of childhood chronic disease. The strategy includes investigating vaccine injuries and pharmaceutical practices but stops short of new regulatory action. Kennedy unveiled the MAHA strategy joined by Agriculture Secretary Brooke Rollins, EPA Administrator Lee Zeldin, and other top Trump officials. Critics noted significant gaps, however: when Kennedy released a long-awaited MAHA report focused specifically on improving children's health, it was widely assumed he would take aim at pesticides, but that did not happen. The report endorsed new research related to pesticides but otherwise said very little on the subject.

Agency Restructuring and Budget Cuts

Since entering office in February 2025, Kennedy oversaw a dramatic reshaping of the agencies he oversees, including eliminating thousands of jobs and freezing or canceling billions of dollars for scientific research. Within two months of taking office, Kennedy announced a sweeping restructuring of HHS that would shut down entire agencies, consolidate others into a new one focused on chronic disease, and lay off some 10,000 employees on top of 10,000 others who had already taken buyouts. While parts of the effort are still tied up in court, thousands of the mass layoffs were allowed to stand, and those and voluntary departures significantly thinned out the sprawling department.

Under the proposed FY 2026 budget, HHS's discretionary funding would be cut from $127 billion to $95 billion, while the NIH would lose almost $18 billion of its discretionary budget. The NIH's 27 institutes would be trimmed down to just eight, though the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Institute on Aging would survive with smaller budgets. Biotech investors and researchers have warned that the planned cuts could stifle U.S. medical innovation at a time when the country's biopharmaceutical industry is losing ground to China.

A coalition of 19 state attorneys general filed suit against HHS, charging that "in its first three months, this administration systematically deprived HHS of the resources necessary to do its job." A federal judge previously granted the states' motion for a preliminary injunction to halt some of the changes.

Vaccine Policy

Since his confirmation, Kennedy has toed the line between backing vaccination as a preventive public health tool and making statements or overseeing developments that threaten to undermine it. Kennedy, along with NIH Director Jay Bhattacharya and FDA Commissioner Marty Makary, announced that the CDC would no longer recommend the COVID vaccine for healthy children and pregnant women. Kennedy also said a commission would investigate the childhood vaccination schedule, questioning whether it was among "possible factors" tied to poor health in the U.S., and said the MAHA commission would convene "representatives of all viewpoints" to examine potential causes behind a "drastic rise in chronic disease."

The entire staff of the federal government's Office of Infectious Disease and HIV/AIDS Policy was laid off as part of the broader restructuring plan ordered by Kennedy involving cutting HHS positions. The department's rapid transformation garnered praise from MAHA supporters, and both Democrats and Republicans applauded some of the agency's actions, including efforts to encourage healthy eating and exercise and deals to lower the prices of costly drugs. However, many of the drastic changes Kennedy led at the department raised grave concerns among doctors and public health experts.

Recent Developments

Kennedy reached an "understanding" with food industry companies rather than a binding mandate on food dyes and additives, and by early 2026 roughly 40 percent of the packaged food supply had pledged near-term removal of certain additives. On drug pricing, by December 2025, 16 pharmaceutical companies had signed voluntary agreements to sell drugs to Medicaid at most-favored-nation-aligned prices in exchange for a three-year tariff reprieve.

In April 2026, Kennedy publicly criticized Senator Bill Cassidy after the Trump administration pulled Casey Means' nomination to be surgeon general. Her nomination had stalled over concerns about her experience and her past comments on vaccines. Kennedy accused Cassidy of doing "the dirty work for entrenched interests seeking to stall the MAHA movement."

The HHS overhaul has come alongside broader uncertainties in the nation's health system, including Medicaid cuts passed by Congress and expiring Affordable Care Act subsidies that are putting millions of Americans' insurance coverage in jeopardy. Litigation over the restructuring of federal health agencies remains ongoing as of August 2026.

Outlook

Kennedy's tenure remains one of the more consequential and contested of the Trump Cabinet. His MAHA agenda has achieved genuine traction in areas such as food policy and drug pricing negotiations, and has attracted bipartisan sympathy in some quarters. But the scale of agency restructuring, the departure of thousands of career public health employees, and his handling of vaccine policy have generated sustained legal and political opposition. The contradiction between MAHA's stated goals and the administration's broader cuts to nutrition assistance, research funding, and environmental enforcement has become a recurring line of criticism from both public health professionals and Kennedy's own supporters. How courts ultimately resolve the ongoing litigation over HHS restructuring, and whether Congress approves the administration's proposed budget cuts to NIH and other agencies, will substantially determine the lasting shape of Kennedy's legacy at HHS.